MAPT and Alzheimer disease: National Institute on Aging and the Alzheimer’s Association (NIA-AA) and DSM-5 describe AD as a neurocognitive disorder with the gradual decline or loss of cognitive abilities, with potential biomarkers such as accumulation of amyloid beta Aβ and phosphorylated tau protein, some AD cases predisposed due to genetic mutation [59].